Received: 3 June 2020
Accepted: 16 September 2020
First Online: 24 September 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all survey participants. Given the nature of this market research project, Clinical Research Ethics Committee and/or Independent Review Board approval was not required, according to the EphMRA code of conduct (Section 1.3). The research team complied with all European laws protecting personal data. To comply with General Data Protection Regulation, data were only collected from the 124 people who completed the survey questionnaire and all responses were anonymised. The research team complied with the ESOMAR, EphMRA, MRS and BHBIA codes of conduct.
: Written informed consent was obtained from participants for publication of aggregated, anonymised survey responses.
: Tokunbo Soyemi and Darcy Bowman are employees of Gilead Sciences Europe Ltd. and may own stock or stock options. Marta Torrens has received consultancy fees from AbbVie, Esteve, Gilead Sciences, Lundbeck, Merck Sharp & Dohme and Servier. The Correlation European Harm Reduction Network receives funding from Gilead Sciences for hepatitis C-related research and activities.